Predisposition Biomarkers Sector: Growth Drivers and Challenges
Growth Drivers
- Increasing Prevalence of Chronic Diseases, Such as, Cancer, and Diabetes
- Advancement in Diagnostic Technology
- Ease of Availability and Use of Biomarkers
Challenges
- Lack of Efficient Healthcare System in Developing Countries
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
Predisposition Biomarkers Market size is expected to register remarkable growth rate during the forecast period i.e., between 2025-2037.
Rising prevalence of the acute and chronic disease, and growing R&D investment for medical research will impel the market growth.
North America industry is poised to account for largest revenue share by 2037, owing to undergoing advanced research and development in the healthcare sector along with innovative clinical experiments, and development of new diagnostic tools.
The major players in the market are Danaher Corporation, Biomarker Technologies, Inc., Almac Group Limited, Myriad Genetics, Inc., F. Hoffmann-La Roche Ltd, Epigenomics AG, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., QIAGEN GmbH and others.
